[ad_1]
NEW DELHI: The Indian Pharmacopoeia Commission (IPC) has issued a drug safety alert urging healthcare professionals and patients to monitor adverse reactions associated with the painkiller Meftal, commonly prescribed for menstrual cramps and rheumatoid arthritis.
Meftal, which contains mefenamic acid, is used in the treatment of conditions such as rheumatoid arthritis, osteoarthritis, dysmenorrhea, mild to moderate pain, inflammation, fever, and dental pain.
The commission’s alert, issued on November 30, highlighted a preliminary analysis of adverse drug reactions from the Pharmacovigilance Programme of India (PvPI) database, revealing instances of drug reactions leading to eosinophilia and systemic symptoms (DRESS) syndrome.
“Healthcare professionals, patients/consumers are advised to closely monitor the possibility of the above adverse drug reaction (ADR) associated with the use of the suspected drug,” according to the alert, issued on November 30.
In the event of such reactions, individuals are encouraged to report the matter to the national coordination centre of the PvPI under the commission. This can be done by filing a form on the website www.ipc.gov.in or through the android mobile app ADR PvPI and the PvPI Helpline No. 1800-180-3024.
As an autonomous institution of the Ministry of Health, the IPC establishes standards for all drugs manufactured, sold, and consumed in India.
(With inputs from agencies)
Meftal, which contains mefenamic acid, is used in the treatment of conditions such as rheumatoid arthritis, osteoarthritis, dysmenorrhea, mild to moderate pain, inflammation, fever, and dental pain.
The commission’s alert, issued on November 30, highlighted a preliminary analysis of adverse drug reactions from the Pharmacovigilance Programme of India (PvPI) database, revealing instances of drug reactions leading to eosinophilia and systemic symptoms (DRESS) syndrome.
“Healthcare professionals, patients/consumers are advised to closely monitor the possibility of the above adverse drug reaction (ADR) associated with the use of the suspected drug,” according to the alert, issued on November 30.
In the event of such reactions, individuals are encouraged to report the matter to the national coordination centre of the PvPI under the commission. This can be done by filing a form on the website www.ipc.gov.in or through the android mobile app ADR PvPI and the PvPI Helpline No. 1800-180-3024.
As an autonomous institution of the Ministry of Health, the IPC establishes standards for all drugs manufactured, sold, and consumed in India.
(With inputs from agencies)
#Meftal #IPC #raises #alert #adverse #reactions #meftal #painkiller #India #News
